ClinicalTrials.gg
RecruitingNCT07318805Updated Nov 5, 2026

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of PF-08032562 and Fulvestrant in Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) and Colorectal Cancer, sponsored by Pfizer. Recruiting at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 5, 2026First sites in France and Spain4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
260
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Triple Negative Breast Neoplasms by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Triple Negative Breast Neoplasms · Pfizer.

Planned enrollment
4th of 18
260 · median 122
Started
2025
the only one that year
Phase 1
13 of 18
2 open now
Registered
18th of 18
by date

Among the 18 studies in Triple Negative Breast Neoplasms by Pfizer, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 13 in phase 1, and was the 18th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

2 of the 18 studies in Triple Negative Breast Neoplasms by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Triple Negative Breast Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication.

This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC).

All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles.

Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.

03

Conditions studied

  • Advanced Breast Cancer
  • Metastatic Breast Cancer (HR+/ HER2-)
  • Colorectal Cancer
  • Metastatic Colorectal Adenocarcinoma
  • Triple Negative Breast Cancer

Keywords

  • Carcinoma, Breast
  • Estrogen Receptor Positive Breast Cancer
  • HER2- Breast Cancer
  • Triple Negative Breast Cancer
  • Colon Cancer
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

This study's planned enrollment of 260 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Advanced or cancer of the breast or colon Part 1A: metastatic or advanced breast cancer or colorectal cancer for which no standard therapy is available Part 1B: metastatic or advanced breast cancer with disease progression after at least 1 with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting Part 1C: metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 1D: metastatic or advanced colorectal cancer without any prior chemotherapy for advanced or metastatic disease Part 2A: metastatic or advanced breast cancer with disease progression after at least 1 prior line of CDK4/6 inhibitor and at least 1 prior line of endocrine therapy Part 2B: metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2C: metastatic or advanced colorectal cancer without any prior chemotherapy for advanced or metastatic disease
  • performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Active within 3 years prior to enrollment
  • Known symptomatic requiring
  • Advanced/, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
  • Prior irradiation to >25% of the bone marrow
  • Hypertension that cannot be controlled by optimal medical therapy
  • Renal impairment
  • Hepatic dysfunction
  • Cardiac abnormalities
  • Active bleeding disorder
  • Active or history of GI disease
  • Other unacceptable abnormalities as defined by protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Part 1 Dose Escalation Cohort 1A

    PF-08032562 monotherapy dose escalation for participants with advanced or metastatic BC or CRC, at different doses and/or schedules of the study drug

    Drug: PF-08032562

  • Experimental
    Part 1 Dose Escalation Cohort 1B

    Combination (PF-08032562 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses and/or schedules of the study drug

    Drug: PF-08032562 · Drug: Fulvestrant

  • Experimental
    Part 1 Dose Escalation Cohort 1C

    Combination (PF-08032562 + cetuximab) dose escalation for participants with advanced or metastatic CRC, at different doses and/or schedules of the study drug

    Drug: PF-08032562 · Drug: Cetuximab

  • Experimental
    Part 1 Dose Escalation Cohort 1D

    Combination (PF-08032562 + \[FOLFOX + bevacizumab\]) dose escalation for participants with advanced or metastatic CRC, at different doses and/or schedules of the study drug

    Drug: PF-08032562 · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Bevacizumab

  • Experimental
    Part 2 Dose Expansion Cohort 2A

    Combination (PF-08032562 + fulvestrant) dose expansion for participants with advanced or metastatic BC, at different doses and/or schedules of the study drug

    Drug: PF-08032562 · Drug: Fulvestrant

  • Experimental
    Part 2 Dose Expansion Cohort 2B

    PF-08032562 monotherapy or combination (PF-08032562 + cetuximab) dose expansion for participants with advanced or metastatic CRC, at different doses and/or schedules of the study drug

    Drug: PF-08032562 · Drug: Cetuximab

  • Experimental
    Part 2 Dose Expansion Cohort 2C

    Combination (PF-08032562 + \[FOLFOX + bevacizumab\]) dose expansion for participants with advanced or metastatic CRC, at different doses and/or schedules of the study drug

    Drug: PF-08032562 · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Bevacizumab

Interventions

  • DrugPF-08032562

    Taken by mouth (PO)

  • Selective Estrogen Receptor Degrader (SERD)

    Also known as: Faslodex

  • Monoclonal antibody (EGFR inhibitor)

    Also known as: Erbitux, Enlituo

  • Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

    Also known as: 5-FU, 5-Fluorouracil

  • Part of FOLFOX chemotherapy regimen platinum based compound (alkylating agent)

    Also known as: Eloxatin

  • Part of FOLFOX chemotherapy regimen (folic acid analog)

    Also known as: Folinic Acid, Wellcovorin, Calcium Folinate

  • Monoclonal antibody (VEG-F inhibitor)

    Also known as: Zirabev, Avastin

07

What researchers measure

Primary outcomes

  1. Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)

    Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.

    Time frame: Baseline up to 28 days

  2. Part 1 (Dose Escalation): Number of participants with laboratory abnormalities

    Number of participants with laboratory test abnormalities.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  3. Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  4. Part 2 (Dose Expansion): Objective Response Rate (ORR)

    ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

Secondary outcomes

  1. Part 1 & Part 2: Maximum Observed Serum Concentration (Cmax)

    Evaluate the single and multiple dose PK of PF-08032562 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  2. Part 1 & Part 2: Time to Reach Maximum Observed Serum Concentration (Tmax)

    Evaluate the single and multiple dose PK of PF-08032562 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  3. Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)

    Evaluate the single and multiple dose PK of PF-08032562 as monotherapy, or in combination with other anti-tumor agents.

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  4. Part 1: Effect of Food on Cmax

    Evaluate the effect of food on Cmax of PF-08032562 as monotherapy

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  5. Part 1: Effect of Food on Tmax

    Evaluate the effect of food on Tmax of PF-08032562 as monotherapy

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  6. Part 1: Effect of Food on AUClast

    Evaluate the effect of food on AUClast of PF-08032562 as monotherapy

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  7. Part 1: Percent change of immune cells within tumors based on immunohistochemistry assessment

    Evaluate the single and multiple dose pharmacodynamics of PF-08032562 as monotherapy, or in combination with other anti-tumor agents. This measure will assess change in the concentration of immune cell-related cytokines and chemokines as potential pharmacodynamic effects of PF-08032562 using Immunohistochemistry (IHC) assays.

    Time frame: Baseline through end of Cycle 1 (each cycle is 28 days)

  8. Part 2 (Dose Expansion): Number of participants with laboratory abnormalities

    Number of participants with laboratory test abnormalities.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  9. Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

    Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

  10. Part 1 & Part 2: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  11. Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1

    DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  12. Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1

    CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  13. Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1

    DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  14. Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1

    PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  15. Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1

    TTR is defined as the time from start date of treatment to first documentation of CR or PR.

    Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

  16. Part 2: Overall Survival (OS)

    OS is defined as time from from start date of treatment to the date of death due to any cause

    Time frame: Up to approximately 2 years

08

Study locations

13 of 17 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2029, 39 months after the start.

Of 136 industry-sponsored phase 1 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 70. This study's planned 39 months is below that.

Counting every sponsor, half of 209 studies reached it within 54 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Jan 6, 2026
StartActual
Dec 23, 2025
Primary completionEst.
Apr 14, 2029
CompletionEst.
Apr 14, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added — first sites in France and Spain
Show 4 added (2 France, 2 Spain)
  • Gustave Roussy · Villejuif, France
  • CHU Poitiers · Poitiers, France
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Universitario HM Sanchinarro · Madrid, Spain
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    4 sites added — first sites in France and Spain
    Show 4 added (2 France, 2 Spain)
    • Gustave Roussy · Villejuif, France
    • CHU Poitiers · Poitiers, France
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Universitario HM Sanchinarro · Madrid, Spain
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07318805
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Dec 23, 2025
Primary completion
Apr 14, 2029 (estimated)
Completion
Apr 14, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion